compare trans-vesical prostatectomy with transurethral resection of the prostate

Men aged 50–70 years, diagnosed with BPH of prostate size ≥ 80 and meeting inclusion criteria were randomly assigned to undergo either TVP or TURP. Preoperative evaluations, surgical procedures, and postoperative follow-up assessments were conducted according to standardized protocols. Primary endpoints included International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), and post-void residual volume (PVR). Secondary endpoints encompassed complications and adverse events This was a randomized clinical trial conducted on 100 cases at the Urology Department of Qena University Hospital

Of 136 included patients, after matching 100 patients received allocated intervention. 50 patients from each group with comparable baseline characteristics were included. There was highly statistically significant variance among both groups as regards operation time and catheter duration, but there wasn’t significant variance as regards hospital stay, 3-month follow-up, and 6-month follow-up results of the IPSS score. There was significant variance as regards clot retention and stricture, but there wasn’t significant variance among the two groups as regards blood transfusion, fever, incontinence, and recurrence.

Demographic distribution and The prostatic data showed in Total and free PSA between the study populations shows no statistical significant difference between the two groups. 

Regarding preoperative data and prostate assessment; Hemoglobin levels among the study population. Hb  in TVP group with statistical significant difference  between the two groups.

As operative data outcome between the study population showed in Table  a significant longer mean operative time for patients underwent TURP On the other hand, TVP was associated with longer hospital stay and longer catheter duration in comparison with same parameters in TURP group which were with statistical significant difference  between the two groups.
 
Regarding postoperative outcome and Incidence of adverse events between the study population  showed in Blood transfusion there was no statistical significant difference between the two studied groups . Regarding Clot retention, there was a significant difference between the two studied groups . Regarding Fever, there was no statistical significant difference between the two studied groups . Regarding Incontinence, there was no statistical significant difference between the two studied groups. Regarding Stricture, there was a significant difference between the two studied groups . Regarding Recurrence, there was no statistical significant difference between the two studied groups.

Follow up results of PVR , IPSS score and Qmax among the study population in T showed three months follow up IPSS score in TVP group  while in TURP group the Three months follow up IPSS score  with highly statistical significant difference between the two groups. Six months follow up IPSS score in TVP group  while in TURP group the Six months follow up IPSS score with highly statistical significant difference between the two groups. As regarding Qmax, three months follow up Qmax in TVP group ile in TURP group the Three months follow up Qmax  with highly statistical significant difference between the two groups. Six months follow up Qmax in TVP group m while in TURP group the Six months follow up Qmax with highly statistical significant difference between the two groups. Follow up results of PVR  among the study population. Three months follow up PVR  in TVP group while in TURP group the Three months follow up PVR   with highly statistical significant difference  between the two groups. Six months follow up PVR in TVP group while in TURP group the Six months follow up PVR with highly statistical significant difference between the two groups.

This randomized clinical trial provides valuable insights into the comparative effectiveness and safety of TVP and TURP for BPH in the context of Qena University Hospital, Trans-vesical prostatectomy (TVP) remains effective.

1.	FOO, Keong Tatt. (2019). What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World journal of urology, 37: 1293-1296. ?
2.	LERNER, Lori B., et al. (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management. The Journal of urology, 206.4: 806-817
4.	ZHANG, Jian, et al. Efficacy and safety evaluation of transurethral resection of the prostate versus plasmakinetic enucleation of the prostate in the treatment of massive benign prostatic hyperplasia. Urologia Internationalis, 2021, 105.9-10: 735-742.?